Hubbry Logo
HidradenitisHidradenitisMain
Open search
Hidradenitis
Community hub
Hidradenitis
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hidradenitis
Hidradenitis
Hidradenitis
View on Wikipedia
from Wikipedia
Hidradenitis
SpecialtyDermatology Edit this on Wikidata

Hidradenitis is any disease in which the histologic abnormality is primarily an inflammatory infiltrate around the eccrine glands.[1]: 780  This group includes neutrophilic eccrine hidradenitis and recurrent palmoplantar hidradenitis.[1]: 780 

It can also be defined more generally as an inflammation of sweat glands.[2]

Hidradenitis suppurativa is a chronic cutaneous condition originally thought to be primarily characterized by suppurative inflammation of the apocrine sweat glands.[3]: 710  Recent evidence supports that the primary event is follicular hyperkeratosis and obstruction,[4] but the term hidradenitis supperativa has continued to be used in major medical journals.[5]

Symptoms

[edit]

Hidradenitis suppurativa is a chronic inflammatory skin condition, considered a member of the acne family of disorders.[6] It is sometimes called acne inversa. The first signs of HS are small bumps on the skin that resemble pimples, cysts, boils, or folliculitis. As the disease progresses and abscesses reoccur, they become larger and more painful; eventually tunnels of scar tissue connect the lesions. These lesions may open up if they become too enlarged and drain bloodstained pus.[7]

Risk factor

[edit]

One risk factor is age; HS usually starts after puberty, usually in the teens and twenties.[8] The condition is much more common in women than in men but is usually more serious and debilitating in men. Other associated conditions include obesity, diabetes, metabolic syndrome, arthritis, acne, and other inflammatory disorders. Early diagnosis of this disease is very important to decrease the number of flares, pain, and discomfort.[7]

Treatment

[edit]

The Mayo Clinic suggests the following: antibiotics (generally the lowest side effect profile compared to other treatments); corticosteroids (e.g., prednisone); but corticosteroids have many side effects, including "moon face" for the duration of the medication's trial usage, as well as unwanted hair growth for females and/or osteoporosis with long-term use. Tumor necrosis factor (TNF)-alpha inhibitors like infliximab (Remicade) and adalimumab (Humira) have shown promise for some, but they should probably be considered a third-line treatment, as treatment is associated with increased risk of infection, heart failure and certain cancers. Surgery is also available for those overwhelmed by the condition, but it will not cure the condition, just relieve the skin-related issues for a while. The disease is pernicious and is almost always guaranteed to return, if not in the same spot where the surgery was performed.[9]

Some products for adult acne may help relieve some symptoms for people with hidradenitis, although there is no guarantee it will work in all or even most individuals. Birth control medication may relieve some symptoms for women; there is a hormonal treatment for men as well, but that has not been proven to be safe or effective as of yet.[10]

Alternative treatments not approved by the FDA include alpha hydroxy acids (naturally available in small amounts in citrus fruits), Azelaic acid, and zinc. It is not thought that they are as effective as standard medical treatment, but they tend to have less side effects. Some suggest tea tree oil and a specific strain of brewer's yeast, called CBS 5926. However, tea tree oil can cause contact dermatitis for some as well as breast development in teenage boys and should not be used if one has rosacea due to the potentiality of worsening the symptoms of that skin condition. CBS 5962 can also cause migraines and intestinal issues for some.[11]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Hidradenitis

View on Grokipedia
from Grokipedia
(HS), also known as inversa, is a chronic inflammatory that primarily affects hair follicles in areas where the skin rubs together, such as the armpits, , and under the breasts, leading to recurrent painful lumps, abscesses, draining sinus tracts, and scarring. The condition typically begins with small, tender nodules that resemble boils or but progress to form deep-seated abscesses filled with , which may rupture and release foul-smelling discharge; over time, these lesions interconnect via tunnels (sinus tracts) beneath the skin, resulting in chronic and . Symptoms often worsen with friction, heat, or sweating and can cause significant , restricted movement, and emotional distress due to their location and appearance. HS is classified into three stages using the Hurley system: stage I involves single or multiple abscesses without sinus tracts; stage II features recurrent abscesses with sinus tracts and scarring; and stage III presents as widespread interconnected lesions with extensive scarring. The exact cause of HS remains unclear, but it involves a combination of , immune dysregulation, and environmental factors, beginning with occlusion and rupture of follicles that triggers an inflammatory response. Approximately 33-40% of patients have a family history, suggesting an autosomal dominant pattern in some cases. Risk factors include , , female sex (women are affected three times more often than men), and onset typically between ages 20 and 40. Associated comorbidities include , , and depression, highlighting its systemic impact. Diagnosis is primarily clinical based on history and physical examination, often delayed by an average of seven to ten years due to misdiagnosis as simple infections; biopsies or imaging like ultrasound may be used in ambiguous cases. Treatment focuses on symptom management and disease modification, as HS is incurable, and includes lifestyle modifications (, ), topical and oral antibiotics (e.g., clindamycin), anti-inflammatory drugs, biologics such as , , and bimekizumab (FDA-approved therapies), and surgical interventions like wide excision for severe cases. Complications can include , , , and a rare increased risk of in chronic lesions. Early intervention improves and reduces progression.

Signs and symptoms

Lesion types

Hidradenitis suppurativa manifests through a spectrum of primary skin lesions that typically begin as deep-seated, inflammatory nodules measuring 0.5 to 2 cm in diameter, often described as pea-sized and resembling boils. These nodules are erythematous, firm, and intensely tender to , arising from follicular occlusion and subsequent in gland-bearing skin. They may persist for days to months before potentially rupturing, releasing serosanguinous or purulent, malodorous discharge. Secondary lesions develop as complications of unresolved primary nodules, progressing to abscesses characterized by collections of within fluctuant, swollen masses that exacerbate local . Rupture of these abscesses can lead to the formation of draining sinus tracts or tunnels, which are subcutaneous passages that intermittently discharge purulent material and contribute to chronicity. These manifestations can be particularly evident in the breast region, where deep subcutaneous nodules or abscesses may rupture, drain pus, form sinus tracts, and heal with ropelike, pitted, or atrophic scarring resembling acne scars. Following resolution of active , fibrotic scarring occurs, resulting in thick, rope-like bands, pitted, or atrophic scarring that may resemble acne scars, or hypertrophic plaques that distort the skin's architecture. Distinctive comedonal structures in include open "tombstone" comedones, which represent dilated follicular ostia filled with plugs, and double-ended pseudocomedones, which appear as paired, blackhead-like lesions connected by a subcutaneous tract unique to the areas affected by the disease.30902-7/fulltext) These pseudocomedones arise from the rupture and reformation of follicular units, differing from typical comedones due to their bidirectional drainage. The sensory experience of these lesions is dominated by intense pain, stemming from acute inflammatory processes that release cytokines and from mechanical pressure exerted by expanding nodules and abscesses on underlying nerves. This nociceptive and potentially can radiate beyond the lesion site, described by patients as throbbing or burning, and significantly impairs daily function.02814-7/fulltext) In advanced cases, persistent sinus tracts may evolve into chronic tunnels, perpetuating cycles of pain and discharge.

Disease progression

Hidradenitis suppurativa typically begins with acute flares characterized by the development of painful nodules or abscesses in areas, which often resolve spontaneously within 1 to 4 weeks. These early lesions, such as single or multiple abscesses without sinus tracts or scarring, correspond to Hurley stage I and may be followed by periods of remission lasting weeks to months, during which symptoms subside completely or nearly so. As the disease progresses to a chronic phase, flares become more recurrent, leading to the formation of persistent sinus tracts and fistulas that connect lesions beneath the skin, resulting in ongoing induration and purulent drainage. This corresponds to Hurley stage II, where recurrent abscesses are accompanied by widespread sinus tracts and scarring, and in advanced Hurley stage III, the involvement becomes diffuse with multiple interconnected tracts causing extensive . The frequency of flares varies widely, from infrequent episodes in mild cases to near-daily drainage and active in severe, longstanding disease. Repeated over time drives the scarring process, producing either hypertrophic scars—raised, firm plaques or rope-like bands—or atrophic scars, which appear as depressed, smooth, or cribriform depressions in the .30234-6/fulltext) In severe cases, these scars can lead to contractures that restrict skin mobility and cause functional impairment.

Affected body areas

Hidradenitis suppurativa predominantly involves regions rich in glands, where the skin folds create an environment conducive to disease manifestation. The axillae represent the most common site of involvement, followed by the inguinal folds, perianal and perineal areas, inframammary folds, breasts, and . HS can affect the breast skin itself in addition to the inframammary folds, often presenting as deep painful nodules or abscesses accompanied by pitted or atrophic scarring on the breast skin that may resemble acne scars. Less frequently affected areas include the upper chest, back, and extremities, with rare occurrences on the face or ears. The distribution is typically bilateral and symmetrical, reflecting the anatomical symmetry of gland-bearing skin. Mechanical factors, such as friction and occlusion within skin folds, play a key role in site predilection and exacerbation, particularly in areas prone to rubbing like the groin and axillae. These influences are more pronounced in individuals with higher body mass index, leading to increased involvement of flexural sites.

Causes and risk factors

Genetic predispositions

Hidradenitis suppurativa (HS) exhibits a significant hereditary component, with approximately 30% to 40% of patients reporting a positive family history of the disease. This familial clustering is observed across various studies, including pediatric cohorts where up to 41% of cases show inheritance patterns. In affected families, the condition often follows an autosomal dominant inheritance with incomplete penetrance, meaning not all individuals carrying the genetic variant develop HS. This pattern underscores the role of genetic susceptibility, though monogenic forms account for only a minority of cases, estimated at less than 7%. Recent genome-wide association studies (GWAS) as of 2024 have identified 11 significant risk loci for HS, with 7 novel signals, highlighting a polygenic architecture involving pathways like Notch and Wnt/β-catenin signaling. Additionally, a 2025 multi-population GWAS confirmed associations near the HLA region, supporting an autoimmune component in non-monogenic cases. Gain-of-function variants in the KDF1 gene have also been linked to HS associated with ectodermal dysplasia. Key genetic associations involve mutations in genes encoding components of the γ-secretase complex, which regulates Notch signaling essential for skin and hair follicle development. Specifically, loss-of-function mutations in NCSTN (nicastrin), PSENEN (presenilin enhancer), and PSEN1 (presenilin 1) have been identified in rare familial forms of HS, with NCSTN mutations being the most common, reported in about 54.5% of such cases. These mutations disrupt γ-secretase activity, leading to impaired Notch pathway function and increased susceptibility to follicular occlusion and inflammation. Additionally, polymorphisms in the promoter region of the TNF gene, such as the -238 variant, are associated with increased disease susceptibility and influence response to anti-TNF therapies. Heritability estimates from twin studies further highlight the strong genetic basis of HS. A large Dutch cohort of over 4,600 twins reported a narrow-sense of 77% (95% CI, 54%-90%), with monozygotic twin concordance at approximately 31% compared to 8% in dizygotic twins. Similarly, a Danish nationwide twin registry study found monozygotic concordance of 28% (95% CI, 7%-49%), yielding a familial 73 times higher than the background , supporting around 80%. These findings indicate that genetic factors explain the majority of HS variance, though environmental interactions modulate expression. Ethnic variations in HS prevalence also suggest genetic influences, with higher rates observed in individuals of African descent. Studies report an average of 1.3% among , compared to 0.07% in Hispanics/Latinos and intermediate levels in Caucasians, pointing to potential ancestry-specific genetic risk factors. Genome-wide association studies have identified variants near genes like SOX9 and KLF5 that may contribute to this disparity, particularly in populations with African ancestry.

Lifestyle and environmental triggers

Obesity is a significant modifiable for (HS), with individuals having a (BMI) greater than 30 kg/m² exhibiting approximately a three-fold increased risk compared to those with lower BMI, primarily due to increased in areas that promotes follicular occlusion and . This association is further supported by higher average BMI values among HS patients (around 27.5 kg/m²) versus controls, correlating with greater disease severity. Smoking substantially elevates HS risk and worsens its course, with tobacco use approximately doubling the incidence rate (0.20% in smokers versus 0.11% in non-smokers) and current smokers demonstrating more severe disease, as measured by higher pack-years and ratios up to 4.16 for disease development. Hormonal factors contribute to HS onset and flares, with the condition typically emerging post-puberty due to androgen-driven activity, and many women (43–76.7%) reporting symptom exacerbation during menstrual cycles linked to and progesterone fluctuations. Additionally, HS patients face a 2.64-fold higher risk of (PCOS), which involves that may amplify disease activity. Common environmental triggers include excessive sweating (), which precedes lesions by 12–48 hours and fosters a moist environment conducive to bacterial proliferation, as well as tight that induces mechanical and irritation in affected areas. Depilation methods such as or can precipitate flares by causing microtrauma to hair follicles, while bacterial overgrowth, particularly involving species, exacerbates despite not being the primary etiology. Observational studies suggest dietary associations with HS flares, including higher intake of products (e.g., cheese and , averaging 222 g/day in patients versus 188 g/day in controls) correlating with increased severity, though causation remains unproven. Similarly, elevated consumption of nightshade vegetables (e.g., tomatoes, potatoes; 237 g/day in patients versus 190 g/day in controls) appears in but lacks strong evidence for direct and shows no clear link to disease staging.

Pathophysiology

Follicular occlusion mechanism

The follicular occlusion mechanism in (HS) is initiated by hyperkeratinization of the , particularly at the infundibulum, which leads to the formation of plugs that obstruct the pilosebaceous unit. This plugging causes progressive dilation of the follicle, culminating in rupture and the release of accumulated contents into the surrounding . The process is considered the primary structural event driving disease onset, distinct from inflammatory responses that follow. Apocrine glands, located in areas such as the axillae and , empty their secretions directly into the upper portion of the canal, above the duct. In the context of follicular occlusion, these glandular secretions mix with debris and sebum within the obstructed infundibulum, contributing to the development of comedone-like structures that exacerbate plugging. Although glands are anatomically proximate and secondarily involved, the primary originates from the follicle rather than glandular dysfunction itself. Bacterial involvement in the follicular occlusion mechanism occurs as a secondary phenomenon, with anaerobes such as species colonizing the dilated and ruptured follicles after initial obstruction. These do not initiate the occlusion but proliferate in the anaerobic environment created by the plug, potentially amplifying tissue damage through chronic . Studies of lesional confirm that such colonization is polymicrobial and opportunistic, supporting the view that play a supportive rather than causal role. Histological examination of early HS lesions reveals dilated hair follicles filled with keratin plugs, often accompanied by mild perifollicular , as observed in biopsies from pre-abscess stages. These findings, including infundibular and epithelial , confirm the occlusion as the inciting event, with rupture evident in subsequent sections. Such early biopsies underscore the mechanical nature of the process before widespread inflammatory infiltration.

Inflammatory processes

Hidradenitis suppurativa (HS) involves dysregulated immune responses that escalate beyond initial follicular occlusion, primarily through overactivation of T helper 1 (Th1) and Th17 pathways in lesional skin. This dysregulation leads to elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interleukin-1 beta (IL-1β), which are significantly higher in HS lesions compared to healthy skin. These cytokines drive a self-perpetuating inflammatory cycle, promoting keratinocyte hyperproliferation and immune cell infiltration. Follicular plugging serves as the initial trigger for this immune escalation. The auto-inflammatory aspects of HS feature prominent neutrophil recruitment, resulting in abscess formation and tissue destruction. Neutrophils infiltrate early lesions, releasing (NETs) that amplify and contribute to the formation of painful subcutaneous . In chronic stages, epithelialized tunnels harbor bacterial biofilms, which sustain persistent by evading immune clearance and promoting recurrent flares. These biofilms, often involving staphylococcal , correlate with higher inflammatory activity in longstanding lesions. Systemic involvement manifests in severe HS cases through elevated acute-phase reactants like (CRP) and (ESR), reflecting broader inflammatory burden. These markers increase with disease severity, as measured by Hurley staging, and are associated with comorbidities such as , including and . Patients with HS exhibit higher rates of metabolic derangements, potentially exacerbating via dysregulation. A genetic-immunologic link underlies this , particularly through gamma-secretase mutations that impair differentiation and enhance signaling pathways. Mutations in genes encoding the gamma-secretase complex, such as NCSTN and PSENEN, disrupt Notch signaling, leading to defective follicular and increased susceptibility to inflammatory triggers. This impairment promotes aberrant production and immune cell activation, bridging to the chronic inflammatory state in HS.

Diagnosis

Clinical evaluation

The clinical evaluation of (HS) begins with a detailed patient to identify characteristic features of the disease. Patients typically report recurrent, painful lumps or nodules in areas, such as the axillae, , or inframammary regions, with lesions persisting for more than two weeks and recurring over months or years. A family is noted in approximately 30-40% of cases, highlighting a genetic component, while risk factors like smoking (prevalent in 70-90% of patients) and obesity are commonly elicited to guide counseling. These historical elements help establish chronicity and recurrence, essential for diagnosis. Physical examination involves thorough inspection and of affected areas to confirm the presence of typical . Inspection reveals deep-seated nodules (0.5-2 cm in size), , sinus tracts, and fibrotic scars in gland-bearing sites, often with evidence of drainage or tunneling. assesses for tenderness, fluctuance indicating abscess formation, and the extent of subcutaneous involvement, which may not be fully apparent on visual exam alone. This step is crucial for documenting lesion morphology and distribution, aiding in differentiation from acute conditions. Basic laboratory tests support the evaluation by assessing for inflammation or secondary . A (CBC) may show if is present, while elevated (CRP) levels indicate active inflammatory processes. In early or mild cases, can detect subclinical sinus tracts or fluid collections, enhancing diagnostic accuracy without invasive procedures. Diagnosis of HS relies on clinical criteria proposed in expert guidelines, requiring at least three key elements: characteristic lesions (e.g., recurrent nodules, abscesses, or draining sinus tracts), typical anatomic locations (e.g., axillae, , ), and chronicity with recurrence over at least six months. These criteria achieve high sensitivity (around 90%) and specificity (97%) for confirming HS based on and exam alone. Once diagnosed, severity staging, such as the Hurley system, may be applied to guide .

Differential diagnoses

Hidradenitis suppurativa (HS) can be challenging to diagnose due to its resemblance to several other dermatologic and systemic conditions, particularly in early stages where painful nodules and abscesses predominate. Accurate differentiation relies on clinical history, distribution in areas, chronic recurrence, and progression to sinus tracts and scarring, which are hallmarks of HS not typically seen in acute infections. Common mimics include , which presents as superficial, perifollicular pustules that resolve quickly with or without antibiotics, lacking the deep nodules and chronicity of HS. Furunculosis, often caused by , manifests as single or isolated deep-seated lesions that respond promptly to or antibiotics, without the multifocal, recurrent pattern in apocrine gland-bearing areas characteristic of HS. , particularly in perianal involvement, may produce fistulas and abscesses mimicking HS, but is distinguished by associated gastrointestinal symptoms such as or , and findings of non-caseating granulomas. Other conditions to consider include , which can form cold abscesses with systemic symptoms like and , confirmed by acid-fast bacilli on culture or , unlike the localized, non-febrile course of uncomplicated HS. presents with chronic suppurative infections featuring sinus tracts and sulfur granules on , often with systemic involvement, differentiating it from HS through microbiologic evidence. Epidermal cysts appear as solitary, non-recurring encapsulated masses that do not form interconnecting tracts, readily identified by imaging or surgical exploration. may simulate advanced HS with ulcerative, indurated growths, but is suspected in cases of atypical rapid progression or non-healing wounds, requiring for keratinizing features. When HS involves the breast area, presenting with deep lumps accompanied by acne-like marks or scarring on the breast skin, it must be differentiated from breast cancer (particularly inflammatory breast cancer, which typically features rapid-onset erythema, peau d'orange skin texture, dimpling, and nipple retraction or inversion rather than recurrent suppurative nodules and pitted or bridged scarring), as well as infectious mastitis, breast abscesses, or cysts. Prompt medical evaluation is essential to rule out malignancy through clinical examination, imaging, and biopsy if indicated, as HS is a clinical diagnosis. HS generally lacks fever or systemic signs unless secondarily infected, contrasting with infectious mimics that often involve acute inflammatory responses and resolution upon antimicrobial therapy. Alternative diagnoses should be suspected in atypical presentations, such as lesions outside sites (e.g., face or extremities), rapid onset without recurrence, or isolated response to antibiotics without scarring.

Staging and classification

Hurley staging system

The Hurley staging system, introduced in 1989 by H.J. Hurley, classifies (HS) severity into three stages based on the anatomical extent of lesions, presence of sinus tracts, and scarring. This simple, clinician-applied tool focuses on observable structural changes rather than subjective symptoms, making it a foundational assessment in . The stages are defined as follows:
StageDescription
ISingle or multiple abscesses without sinus tracts or scarring, limited to one area.
IIRecurrent abscesses with sinus tracts and scarring, featuring widely separated lesions.
IIIDiffuse involvement with multiple interconnected sinus tracts and abscesses across an entire area.
Despite its widespread adoption, the Hurley system has notable limitations as a static snapshot that emphasizes chronic anatomical features over dynamic elements like flare frequency, intensity, or quality-of-life impact. It also shows variability in , particularly for intermediate stages, which can affect consistent application. In , the Hurley staging guides treatment escalation by indicating , such as progressing from topical approaches in stage I to systemic therapies in stages II and III. This utility supports initial patient categorization and communication among healthcare providers, though it is often supplemented by other tools for comprehensive evaluation.

Other assessment tools

In addition to the qualitative Hurley staging system for anatomical classification, several quantitative tools assess (HS) activity, lesion burden, patient impact, and therapeutic response over time. The International HS Severity Score (IHS4) is a dynamic, physician-assessed tool designed for clinical practice and trials to monitor HS progression and treatment efficacy. It calculates a total score by counting inflammatory nodules (1 point each), abscesses (2 points each), and draining tunnels (4 points each), yielding categories of mild (≤3 points), moderate (4–10 points), and severe (≥11 points). Validated in a multicenter study of 236 patients, IHS4 shows good correlation with other severity measures (Spearman's ρ > 0.6) and moderate agreement with patient-reported outcomes. The HS Physician Global Assessment (HS-PGA) provides an overall severity rating based on lesion types and counts, categorizing disease as clear (no s), minimal (1–2 nodules or abscesses), mild (3–5), moderate (6–20), severe (>20 but ≤40 inflammatory lesions), or very severe (>40). Developed to incorporate clinical judgment in trials, it emphasizes active inflammatory elements like nodules and abscesses while excluding scarring. Patient-reported outcomes complement clinical scores by capturing HS's impact on daily functioning. The Dermatology Life Quality Index (DLQI), a 10-item questionnaire spanning symptoms, activities, and relationships, yields scores from 0–30, with higher values indicating greater impairment; in HS cohorts, mean scores of 13–14 reflect very large effects, particularly among females and those with moderate-to-severe disease. Pain, a hallmark symptom, is commonly evaluated using the Visual Analog Scale (VAS) or Numeric Rating Scale (NRS), both 0–10 measures where 0 denotes no pain and 10 the worst imaginable; baseline HS pain averages 6–7, with ≥30% reduction (NRS30) signaling meaningful improvement in trials. Emerging tools enhance detection of subclinical features. Ultrasound-based Sonographic Scoring for HS (SOS-HS) stages disease by counting fluid collections, fistulous tracts, and dermal changes (e.g., pseudocysts), with stages I–III reflecting increasing complexity and involvement of body segments; Doppler modes identify hidden inflammation via vascularization and perilesional , aiding early intervention. The Sartorius score (and its modified version) quantifies extent through counts by type (nodules/abscesses: 1 point; fistulae: 4–6 points), affected regions (up to 9 body areas), and maximum inter-lesion distance per region, enabling longitudinal tracking of mild-to-severe cases.

Management

Medical treatments

Medical treatments for (HS) primarily involve pharmacological interventions aimed at reducing , controlling bacterial overgrowth, and modulating immune responses, with options tailored to disease severity from mild to severe cases. For mild HS, particularly Hurley Stage I, topical therapies serve as first-line management to address localized lesions without systemic exposure. Topical clindamycin, typically applied as a 1% lotion or gel twice daily for up to 12 weeks, is recommended for mild disease due to its antibacterial and properties, helping to reduce nodules and pus-filled areas. , used as a 15% cream applied twice daily during flares and once daily otherwise, provides effects by peeling open clogged follicles and alleviating pain, showing significant improvement in clinical response scores in observational studies. For moderate HS, oral antibiotics are commonly employed for their dual antibacterial and anti-inflammatory actions. Tetracyclines, such as at 100 mg twice daily for 3-6 months, are a standard initial choice, with evidence supporting their use in reducing counts and over 8-12 weeks. A combination of rifampin (300 mg twice daily) and clindamycin (300 mg twice daily) for 8-12 weeks is effective for moderate disease unresponsive to tetracyclines alone, achieving response rates in up to 80% of patients in clinical guidelines. Common side effects of these antibiotics include gastrointestinal upset, such as and . Systemic therapies extend to hormonal agents, retinoids, and immunosuppressants for cases not controlled by antibiotics. , an dosed at 100-200 mg daily in women, reduces lesion counts and pain by modulating hormonal influences on follicular occlusion, with benefits observed in both perimenstrual and non-perimenstrual flares. Retinoids like (typically 0.5-1 mg/kg daily) offer an alternative for refractory mild-to-moderate HS by normalizing follicular keratinization, though their use is limited by potential teratogenicity and mucocutaneous side effects. Immunosuppressants such as (7.5-25 mg weekly) are off-label options for moderate disease, providing anti-inflammatory control but requiring monitoring for and gastrointestinal issues. Biologic agents represent advanced therapy for moderate-to-severe HS, targeting specific cytokines in the inflammatory pathway. Adalimumab, a TNF-alpha inhibitor, received FDA approval in 2015 for adult patients with moderate-to-severe ; the regimen involves an initial dose of 160 mg on day 1, 80 mg on day 15, followed by 40 mg weekly starting day 29, demonstrating significant reductions in abscesses and nodules in pivotal trials. Interleukin-17 inhibitors, including (approved October 2023) and bimekizumab (approved November 2024), provide alternatives for moderate-to-severe HS in adults; is administered as 300 mg subcutaneous injections weekly for the first 5 weeks then every 4 weeks, while bimekizumab, a dual IL-17A and IL-17F inhibitor, is given as 320 mg subcutaneously every 2 weeks up to week 16 then every 4 weeks, blocking IL-17-mediated inflammation and showing improvements in HS severity scores in clinical trials. These biologics may increase infection risk, with common adverse effects including upper respiratory infections and injection-site reactions.

Surgical interventions

Surgical interventions are primarily indicated for advanced or refractory cases of hidradenitis suppurativa (HS), particularly in Hurley stages II and III, where medical therapies alone are insufficient to control disease progression. These procedures aim to remove diseased tissue, alleviate symptoms, and prevent recurrence by addressing the underlying follicular occlusion and inflammatory processes. Prior to surgery, medical stabilization with anti-inflammatory agents is often recommended to reduce active flares and optimize outcomes. Incision and drainage (I&D) is a minimally invasive procedure used acutely for fluctuant abscesses to relieve pain and pressure. It involves incising the skin over the abscess to evacuate and debris, but it is not curative and carries a high recurrence rate due to incomplete removal of underlying sinus tracts and follicular structures. This technique is best suited for isolated lesions and should be avoided as a standalone long-term strategy. Deroofing extends beyond simple by surgically opening and flattening the roof of chronic sinus tracts or interconnected lesions, allowing for by secondary intention while preserving surrounding healthy tissue. This office-based approach is effective for mild to moderate HS (Hurley stage I/II), with studies reporting no recurrence in 83% of treated lesions over a follow-up of 34 months. It is particularly useful for multifocal tracts in areas like the axillae or . Wide local excision involves the complete removal of all affected skin and down to the , typically with 1-2 cm margins to ensure clearance of diseased follicles. Indicated for extensive stage II/III disease, this technique offers the lowest pooled recurrence rate of approximately 8% (95% CI: 2%-16%) across multiple studies, compared to higher rates with partial excisions. Healing can occur via primary closure, secondary , or reconstruction, though it requires careful postoperative care to minimize complications like . Laser therapies provide targeted destruction of hair follicles and coagulation of deeper tissues, serving as adjuncts or alternatives to traditional . (CO2) is commonly used for deroofing and vaporizing sinus tracts, promoting precise tissue removal with reduced and faster recovery. The neodymium-doped yttrium aluminum (Nd:YAG) penetrates deeper for follicular destruction and inflammatory control, with meta-analyses showing significant improvements in HS severity scores (e.g., 31.6% reduction in HS-LASI after two sessions) and lower recurrence when combined with other modalities. These are suitable for localized refractory lesions but may require multiple sessions. Reconstructive options are essential for large defects following wide excision, particularly in cosmetically sensitive or functional areas. Skin grafts, such as split-thickness autografts, achieve high take rates (up to 90%) and heal within about 34 days on average, while local or pedicled flaps (e.g., perforator flaps) provide durable coverage for axillary or perineal sites with minimal donor site morbidity. Timing reconstruction after controlling active helps reduce failure rates, though challenges include and aesthetic concerns. Overall outcomes of surgical interventions demonstrate substantial benefits, with approximately 75% of patients achieving remission in treated areas after a single wide excision procedure. Recurrence rates vary by technique and site, ranging from 5-27% for wide excisions, with lower rates associated with flap reconstruction (around 8%) compared to primary closure (15-22%). Complications such as wound infection (3-5%) and scarring occur but are generally manageable, underscoring surgery's role in improving for severe HS.

Supportive measures

Supportive measures for (HS) encompass non-pharmacological and adjunctive strategies aimed at alleviating symptoms, preventing flares, and enhancing patient well-being. These approaches focus on daily self-management to complement medical therapies, emphasizing , behavioral changes, and emotional coping without addressing curative interventions. care is a cornerstone of supportive management, involving gentle cleansing to minimize risk and promote healing. Patients are advised to use antiseptic washes such as 4% or benzoyl peroxide daily on affected areas, avoiding harsh scrubbing or abrasive tools like loofahs that could exacerbate . For draining lesions, absorbent, non-occlusive dressings are recommended to manage while preventing ; warm compresses applied for 10-15 minutes several times daily can reduce swelling and facilitate drainage. Avoiding occlusive products, tight clothing, and adhesive bandages further prevents friction and bacterial overgrowth in vulnerable sites. Lifestyle modifications play a pivotal role in reducing HS severity and flare frequency. Weight loss of 5-10% body weight in or obese individuals has been associated with decreased inflammatory activity and fewer flares, as demonstrated in small cohort studies where participants experienced symptom improvement after sustained caloric restriction and exercise. is strongly recommended, with evidence indicating that quitting enhances therapeutic responses and lowers disease progression risk, particularly in smokers who comprise a significant portion of HS patients. Additional adjustments include wearing loose-fitting to minimize in intertriginous areas and avoiding triggers like excessive sweating through breathable fabrics. Pain management in HS relies on multimodal supportive techniques to address both acute flares and chronic discomfort. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen provide relief for mild to moderate pain, while warm compresses offer immediate soothing by improving local circulation. For severe episodes, short-term opioids may be considered under medical supervision, alongside topical analgesics like lidocaine for localized application. Non-pharmacological options, including gentle or low-impact activities, can mitigate stiffness without aggravating lesions. Psychological support is essential given HS's impact on , social interactions, and . Counseling or cognitive-behavioral helps patients cope with stigma and isolation, with support groups providing peer education on trigger avoidance and . Patient education programs emphasize the non-contagious nature of HS to reduce anxiety, fostering adherence to management plans. Alternative therapies, such as supplementation, show limited but promising as adjuncts. Oral (90 mg daily) reduced counts and severity in pilot studies of mild HS, potentially due to its properties, though larger trials are needed to confirm efficacy and safety. have emerging support for modulating gut-skin axis , with preliminary data suggesting reduced inflammation in small cohorts, but remains inconclusive without robust randomized controlled trials.

Epidemiology

Prevalence and incidence

Hidradenitis suppurativa (HS) exhibits a global that varies considerably across studies, ranging from 0.05% to 4.1%, with higher estimates often derived from self-reported or questionnaire-based surveys. A 2021 and reported a pooled of approximately 0.4% in population-based studies (95% CI, 0.26%-0.63%) and 1.7% in clinical samples, reflecting methodological differences in case ascertainment. The average worldwide is estimated at 1% as of 2025, though this figure is influenced by regional disparities and study designs. A 2025 estimated global between 0.67% and 1.46%. Incidence rates are less consistently reported but generally range from 0.5 to 3 per 10,000 person-years in population-based cohorts, with some surveys suggesting up to 30 new cases per 10,000 population annually due to broader inclusion criteria. Underreporting significantly impacts prevalence estimates, as HS is frequently misdiagnosed as , boils, or other dermatological conditions, leading to delayed recognition. Stigma associated with the chronic, painful, and sometimes malodorous lesions further discourages patients from seeking care, potentially underestimating the true burden by a factor of several times. Consequently, experts suggest the actual global prevalence may approach or exceed 1%, particularly when accounting for undiagnosed cases in settings. Temporal trends indicate increasing recognition of HS since the , attributed to heightened awareness among clinicians and patients, as well as improved diagnostic criteria. Population-based studies in regions like have shown rising prevalence from 0.12% in 2016 to 0.17% in 2019, possibly reflecting better ascertainment rather than a true epidemiological shift. In , however, incidence and prevalence appear relatively stable, with estimates holding at 0.2-0.4% over recent decades in countries such as and the . Geographic variation is pronounced, with higher prevalence in (up to 0.8-1.4%) and the (0.2-1.2%) compared to and the region, where rates are typically below 0.2%. These differences may stem from genetic factors, environmental influences, or variations in healthcare access and reporting practices, though data from low-prevalence areas remain limited.

Demographic patterns

Hidradenitis suppurativa (HS) typically manifests during early adulthood, with a mean age of onset around 22 years, most commonly between the ages of 20 and 40. The disease is rare in children, occurring only occasionally before , and its incidence decreases significantly after . The condition exhibits a marked predominance, with a female-to-male ratio of approximately 3:1 in Western populations, potentially influenced by hormonal factors such as fluctuations. Men, while less frequently affected overall, tend to experience more severe perianal and gluteal involvement compared to women, who more commonly have axillary and mammary lesions. Ethnic disparities in HS prevalence are notable, with facing a 2- to 4-fold higher risk compared to individuals of European descent, often presenting with more extensive disease. In contrast, prevalence is lower among Asian populations, with rates reported as low as 0.03% to 0.06% in studies from and , versus around 1% globally. HS is also associated with , including components like and , which exacerbate in affected ethnic groups. Common comorbidities among HS patients include , affecting approximately 50% to 70%, and , with prevalence rates of 70% to 90% among diagnosed individuals, both of which are strongly linked to disease onset and severity. Additionally, patients with HS have an increased risk of (prevalence approximately 1-2%) and (prevalence up to 23% in some studies), reflecting shared inflammatory pathways.

Complications

Physical sequelae

Hidradenitis suppurativa (HS) often results in extensive scarring and due to recurrent and tissue destruction, leading to the formation of thick, rope-like bands of particularly in the axillae and regions. These fibrotic changes can cause significant restricted mobility and contractures, impairing function and daily activities in affected areas. In severe, chronic cases involving persistent sinus tracts and tunnels, there is an elevated risk of development, with reported prevalence ranging from 0.5% to 4.6%, predominantly in perianal and gluteal sites among long-standing disease. Lymphatic obstruction from repeated episodes of and scarring contributes to secondary , particularly in advanced HS, with an overall prevalence of approximately 0.9% but higher occurrence in severe, longstanding cases that predispose to recurrent . Chronic HS is associated with , observed in up to 41.3% of patients, often manifesting as due to persistent or from ongoing drainage and blood loss from lesions. may also arise in severe cases, exacerbated by leading to reduced appetite and inadequate nutritional intake. Among systemic effects, secondary AA amyloidosis is a rare complication linked to prolonged inflammation, with a prevalence of about 0.2% in HS patients compared to controls. Anemia of chronic disease further underscores the inflammatory burden in advanced HS.

Psychological impacts

Hidradenitis suppurativa (HS) profoundly impairs quality of life, with patients often reporting severe limitations in daily activities, emotional well-being, and social functioning. The Dermatology Life Quality Index (DLQI) scores among HS patients typically average 12-15, indicating a large to very large effect on quality of life, where scores above 10 signify severe impairment. Depression affects approximately 40-50% of individuals with HS, while anxiety impacts 30-40%, with these rates significantly higher than in the general population and often exacerbated by chronic pain and visible lesions. Social stigma surrounding HS contributes to profound isolation, particularly due to the malodorous drainage from lesions, which leads to , avoidance of social interactions, and feelings of . Patients frequently report withdrawing from relationships and public activities to conceal symptoms, resulting in heightened and reduced disproportionate to disease severity. is prevalent in about 50-60% of HS patients, driven by , genital involvement, and psychological distress, which disrupts intimacy and further strains personal relationships. The condition also affects , with HS-related averaging around 13% of work time and contributing to reduced , job issues, and early or in 10-20% of cases, particularly among those with moderate to severe . Body disturbances from scarring and recurrent lesions intensify these challenges, leading to low self-confidence and avoidance of career opportunities that involve physical exposure or social interaction. Coping strategies, including participation in support groups such as those offered by the Hidradenitis Suppurativa Foundation (HSF), play a crucial role in mitigating psychological burden by fostering , reducing isolation, and enhancing treatment adherence through shared experiences and resources.

Prognosis

Long-term disease course

(HS) is characterized by a chronic, relapsing course, with most patients experiencing recurrent flares of inflammatory lesions throughout their lives. More than 80% of individuals report flares occurring at least monthly, contributing to persistent pain and tissue damage over time. The disease typically manifests with intermittent periods of activity interspersed with partial remissions, but complete is uncommon, occurring in fewer than 20% of cases even after , where symptoms often remain stable or worsen in the majority (44% no change, 40% worsening). activity generally peaks during the third and fourth decades of life, with onset averaging in the early 20s. The average duration of HS from symptom onset is approximately 20-30 years, accounting for a typical diagnostic delay of 7-10 years that prolongs untreated progression. In about half of cases, the disease may "burn out" or significantly reduce in activity by ages 50-60, particularly in women post-menopause, though scarring and residual effects persist. Progression follows patterns classified by Hurley staging: roughly 40-50% of patients remain at mild stage I (isolated abscesses without scarring), 35-40% advance to moderate stage II (recurrent lesions with sinus tracts and separated scarring), and 10-20% reach severe stage III (diffuse interconnected tracts and extensive scarring). Early intervention is crucial, as it can halt advancement to more severe stages in many patients. Mortality in HS is slightly elevated compared to the general population, with an all-cause hazard ratio of approximately 1.15, primarily driven by increased risks from infections, cardiovascular disease, and associated comorbidities rather than the skin condition itself. Cardiovascular mortality, in particular, shows a 58% higher risk in some cohorts.

Factors influencing outcomes

Several factors influence the progression, therapeutic response, and in (HS). Early is a key positive determinant, as diagnostic delays averaging 7-10 years often lead to irreversible structural damage and more severe disease; intervention within approximately 7 years of symptom onset can improve disease control by preventing progression to advanced stages. represents another favorable modifier, reducing the risk of HS development by about 42% compared to continued smoking and improving symptoms in established cases. further enhances outcomes, particularly by augmenting the efficacy of biologic therapies; for instance, significant reductions in body weight (e.g., via GLP-1 agonists like ) have been associated with HS regression and fewer flares in obese patients. Conversely, delayed treatment beyond 10 years correlates with heightened severity and poorer control, as prolonged fosters extensive scarring and sinus tract formation. exacerbates HS staging, with higher linked to increased lesion counts and progression to Hurley stage II or III . Comorbidities such as diabetes mellitus impair and elevate complication risks, particularly in surgical contexts, due to underlying metabolic dysregulation. Regarding therapeutic response, approximately 50-60% of patients with moderate-to-severe HS achieve clinical improvement (e.g., HiSCR50 response) with biologics like , though rates vary by agent and patient factors. Poor prognostic indicators include perianal involvement, which is associated with higher recurrence rates and treatment resistance due to anatomical challenges and formation, and elevated baseline International HS Severity Score (IHS4), which predicts suboptimal responses to owing to greater inflammatory burden. Research gaps persist in long-term outcome data for HS, with limited prospective studies beyond 3-5 years; however, 2025 investigations highlight the potential of approaches using biomarkers (e.g., inflammatory cytokines and metabolic profiles) to tailor therapies and predict responses, and long-term data from trials of newer biologics like bimekizumab demonstrate sustained disease control (e.g., >50% achieving HiSCR at two years).

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK534867/
  2. https://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/symptoms-causes/syc-20352306
  3. https://www.aad.org/public/diseases/a-z/hidradenitis-suppurativa-overview
  4. https://www.aad.org/public/diseases/a-z/hidradenitis-suppurativa-symptoms
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC6330680/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5395382/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6239161/
  8. https://www.aad.org/public/diseases/a-z/hidradenitis-suppurativa-treatment
  9. https://emedicine.medscape.com/article/1073117-treatment
  10. https://dermnetnz.org/topics/hidradenitis-suppurativa
  11. https://pubmed.ncbi.nlm.nih.gov/27983742/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC8176324/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC5402905/
  14. https://journals.cambridgemedia.com.au/wpr/volume-30-number-1/hidradenitis-suppurativa-date-review-clinical-features-pathogenesis-and-therapeutic-approaches
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10353709/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC11933821/
  17. https://www.ovid.com/journals/scms/fulltext/10.12788/j.sder.2017.022~complications-of-hidradenitis-suppurativa
  18. https://emedicine.medscape.com/article/1073117-clinical
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9935031/
  20. https://journals.lww.com/jdds/fulltext/2018/22020/hidradenitis_suppurativa__presenting_at_atypical.9.aspx
  21. https://pubmed.ncbi.nlm.nih.gov/31167568/
  22. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.861241/full
  23. https://www.sciencedirect.com/science/article/abs/pii/S0738081X23001013
  24. https://academic.oup.com/bjd/article/193/5/948/8198020
  25. https://www.medrxiv.org/content/10.1101/2025.06.23.25330121v1
  26. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02475-9/fulltext
  27. https://pubmed.ncbi.nlm.nih.gov/22622421/
  28. https://pubmed.ncbi.nlm.nih.gov/23106544/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7557497/
  30. https://pubmed.ncbi.nlm.nih.gov/34289077/
  31. https://pubmed.ncbi.nlm.nih.gov/33174482/
  32. https://jamanetwork.com/journals/jamadermatology/fullarticle/2807701
  33. http://journalonsurgery.org/pdf/1149.pdf
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC12245869/
  35. https://doi.org/10.1111/bjd.15939
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC9736970/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC11678350/
  38. https://emedicine.medscape.com/article/1073117-overview
  39. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2020.00068/full
  40. https://www.consultant360.com/exclusives/pathophysiology-hidradenitis-suppurativa
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC4257786/
  42. https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2591
  43. https://www.pathologyoutlines.com/topic/skinnontumorhidradenitis.html
  44. https://www.sciencedirect.com/topics/medicine-and-dentistry/hidradenitis-suppurativa
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC11646389/
  46. https://insight.jci.org/articles/view/139932
  47. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02965/full
  48. https://academic.oup.com/bjd/article/192/Supplement_1/i3/7997107
  49. https://pubmed.ncbi.nlm.nih.gov/27564400/
  50. https://www.researchgate.net/publication/307087389_Bacterial_Biofilm_in_Chronic_Lesions_of_Hidradenitis_Suppurativa
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC11025002/
  52. https://www.jaadinternational.org/article/S2666-3287%2824%2900039-7/pdf
  53. https://journals.lww.com/ijd/fulltext/2023/68010/clinical_and_metabolic_characteristics_in.35.aspx
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC8316262/
  55. https://www.jidonline.org/article/S0022-202X%2815%2936117-0/fulltext
  56. https://www.jaad.org/article/S0190-9622(20)32337-X/fulltext
  57. https://hsfoundation.ca/wp-content/uploads/2022/10/JCMS-Hidradenitis-Suppurativa-Practical-Guidelines-CHSF-Paper-August-2022-2.pdf
  58. https://www.aafp.org/pubs/afp/issues/2019/1101/p562.html
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4627882/
  60. https://www.mayoclinic.org/diseases-conditions/inflammatory-breast-cancer/symptoms-causes/syc-20355413
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8344386/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC10861310/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC6850108/
  64. https://ern-skin.eu/wp-content/uploads/2020/08/International-Hidradenitis-Suppurativa-Severity-Score-System.pdf
  65. https://www.sciencedirect.com/science/article/pii/S0738081X23000950
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC7828046/
  67. https://doi.org/10.1016/j.jaad.2023.07.1035
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC11342999/
  69. https://doi.org/10.1016/j.abd.2023.10.003
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC9131892/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9286535/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC7105662/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC10950162/
  74. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125057s410lbl.pdf
  75. https://www.novartis.com/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade
  76. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761151s010lbl.pdf
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC5436059/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC8903230/
  79. https://pubmed.ncbi.nlm.nih.gov/33481433/
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC7670045/
  81. https://pubmed.ncbi.nlm.nih.gov/41201673/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC7948632/
  83. https://pubmed.ncbi.nlm.nih.gov/26470621/
  84. https://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/diagnosis-treatment/drc-20352311
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC10689602/
  86. https://pubmed.ncbi.nlm.nih.gov/25640693/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC9570026/
  88. https://onlinelibrary.wiley.com/doi/10.1111/bjd.19435
  89. https://jamanetwork.com/journals/jamadermatology/fullarticle/2780049
  90. https://pubmed.ncbi.nlm.nih.gov/40864454/
  91. https://academic.oup.com/aje/article/179/12/1477/135435
  92. https://www.emjreviews.com/dermatology/article/hidradenitis-suppurativa-a-retrospective-review-of-13-patients-and-literature-summary/
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC9987236/
  94. https://academic.oup.com/pmj/article/90/1062/216/6992151
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC8156162/
  96. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02848-2/fulltext
  97. https://pubmed.ncbi.nlm.nih.gov/38884313/
  98. https://pubmed.ncbi.nlm.nih.gov/32880911/
  99. https://biomeddermatol.biomedcentral.com/articles/10.1186/s41702-019-0052-0
  100. https://pubmed.ncbi.nlm.nih.gov/36891064/
  101. https://www.dynamed.com/condition/hidradenitis-suppurativa
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC6551578/
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC9687269/
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC8714595/
  105. https://jamanetwork.com/journals/jamadermatology/fullarticle/2782888
  106. https://journals.lww.com/ijdv/fulltext/2022/03000/prevalence_of_acne_inversa__hidradenitis.1.aspx
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC6994573/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC11431364/
  109. https://www.jaadinternational.org/article/S2666-3287(24)00117-2/fulltext
  110. https://jamanetwork.com/journals/jamadermatology/fullarticle/2737815
  111. https://pubmed.ncbi.nlm.nih.gov/34432308/
  112. https://derma.jmir.org/2024/1/e58989/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC11929415/
  114. https://academic.oup.com/bjd/article-abstract/192/1/157/7732959
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC7797412/
  116. https://hspatientguide.com/guide/hs-disease-complications/
  117. https://pubmed.ncbi.nlm.nih.gov/31989656/
  118. https://jamanetwork.com/journals/jamadermatology/fullarticle/2818476
  119. https://www.jaad.org/article/S0190-9622%2809%2901216-X/fulltext
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC9993216/
  121. https://www.sciencedirect.com/science/article/abs/pii/S0190962220304618
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC9628443/
  123. https://www.tandfonline.com/doi/full/10.2147/CCID.S180036
  124. https://www.medpagetoday.com/resource-centers/spondyloarthritis-peer-to-peer/hidradenitis-suppurativa-takes-heavy-toll-sexual-health-regardless-disease-severity/5997
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC8570662/
  126. https://academic.oup.com/bjd/article/188/1/122/6770097
  127. https://www.researchgate.net/publication/367325735_The_impact_of_hidradenitis_suppurativa_on_professional_life
  128. https://www.hs-foundation.org/support-groups
  129. https://www.jaad.org/article/S0190-9622%2819%2932760-4/pdf
  130. https://medicaljournalssweden.se/actadv/article/view/43124/49649
  131. https://www.sciencedirect.com/science/article/pii/S2352647520301143
  132. https://www.sciencedirect.com/science/article/pii/S0736467922004486
  133. https://link.springer.com/article/10.1007/s13671-022-00372-7
  134. https://www.sciencedirect.com/science/article/pii/S0022202X22028901
  135. https://jamanetwork.com/journals/jamadermatology/fullarticle/2491691
  136. https://pubmed.ncbi.nlm.nih.gov/38572195/
  137. https://www.actasdermo.org/en-hidradenitis-suppurativa-need-for-early-articulo-S157821901930143X
  138. https://www.medcentral.com/dermatology/hidradenitis-suppurativa-risk-reduces-over-smoke-free-years
  139. https://pubmed.ncbi.nlm.nih.gov/31502868/
  140. https://www.ajmc.com/view/semaglutide-improves-hidradenitis-suppurativa-in-patients-with-obesity
  141. https://pmc.ncbi.nlm.nih.gov/articles/PMC7592906/
  142. https://pubmed.ncbi.nlm.nih.gov/24577555/
  143. https://karger.com/sad/article/9/3/187/835931/Metformin-in-Hidradenitis-Suppurativa-Is-It-Worth
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC11663038/
  145. https://pmc.ncbi.nlm.nih.gov/articles/PMC10590627/
  146. https://pubmed.ncbi.nlm.nih.gov/35322692/
  147. https://www.researchgate.net/publication/389436206_Hidradenitis_suppurativa_from_basic_science_to_surgery_and_a_new_era_of_tailored_targeted_therapy_An_expert_opinion_paper
  148. https://pmc.ncbi.nlm.nih.gov/articles/PMC12354943/
  149. https://www.emjreviews.com/dermatology/news/hidradenitis-suppurativa-long-term-data-shows-lasting-relief/
Add your contribution
Related Hubs
User Avatar
No comments yet.